KSQ Therapeutics
The ambition to cure
- Headquarters
- Lexington, Massachusetts
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- ksqtx.com
- Total Funding
- $156.0M
- Last Round
- $80.0M Series CSep 2018
- Rounds
- 2
About
KSQ Therapeutics is a clinical-stage biotechnology company headquartered in Lexington, Massachusetts. Founded in 2015 and backed by Flagship Pioneering, KSQ has industrialized genome-wide CRISPR/Cas9 functional genomic screens (CRISPRomics platform) across cancer models and immune cell types to identify high-confidence therapeutic targets. The company's lead programs are eTIL (engineered Tumor-Infiltrating Lymphocyte) therapies, which knock out SOCS1 and Regnase-1 targets to dramatically boost T cell tumor-killing activity. KSQ has strategic partnerships with Takeda, Ono, and Roche for immuno-oncology programs, and has raised over $156M in funding. The company is advancing multiple eTIL candidates including KSQ-001EX and KSQ-004EX.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sep 2018
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...